Updated:
U.S. Food and Drug Administration
Established in 1906 with the signing of the Pure Food and Drugs Act by President Theodore Roosevelt, the FDA began as a single chemist's enforcement unit...
U.S. Food and Drug Administration
Established in 1906 with the signing of the Pure Food and Drugs Act by President Theodore Roosevelt, the FDA began as a single chemist's enforcement unit within the Department of Agriculture. Its mandate expanded decisively in 1938 after the Elixir Sulfanilamide disaster killed over 100 people, granting the agency authority to require pre-market safety testing for new drugs. Today the agency operates under the Department of Health and Human Services, employing thousands of scientists, physicians, and inspectors across its Silver Spring, Maryland headquarters and field laboratories nationwide. The FDA's regulatory footprint spans human and veterinary drugs, biologics, medical devices, food safety, cosmetics, and tobacco products through six product centers. The Center for Drug Evaluation and Research (CDER) alone approved 55 novel drugs in 2023 (per public record). The agency's decisions on priority review vouchers, breakthrough therapy designations, and accelerated approval pathways function as de facto value signals that public and private investors track closely. Its power to issue complete response letters — effectively rejecting a drug application pending further data — can erase billions in market capitalization overnight. Structurally, the FDA is funded through a mix of Congressional appropriations and user fees paid by the industries it regulates. The Prescription Drug User Fee Act (PDUFA), first enacted in 1992 and reauthorized every five years, ties agency funding to review-timeline commitments, creating a unique public-private financing model. Recent operational shifts include the September 2023 reorganization of the Office of Regulatory Affairs into a unified Human Foods Program (per the agency, 2023), consolidating food safety functions that had been split across multiple centers. What distinguishes the FDA among global regulators is its combination of scientific reviewer headcount and direct market authority — no comparable agency has larger pre-market review capacity paired with jurisdiction over the world's most profitable pharmaceutical market. The accelerated approval pathway, formalized in 1992, created a structure where drugs can reach the market based on surrogate endpoints with post-market confirmatory trial requirements, a mechanism that has fundamentally shaped oncology drug development economics.
General information
Firm type
other
Year founded
1906
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Silver Spring
Corporate office
Silver Spring, MD, United States
Sector focus
Frequently asked questions
What is the FDA's legal authority to block a product from the market?
Under the Federal Food, Drug, and Cosmetic Act, the FDA requires pre-market approval for new drugs, biologics, and high-risk medical devices. Sponsors must submit clinical trial data demonstrating safety and efficacy, and the agency can issue a complete response letter rejecting the application if the evidence is insufficient. For food and cosmetics, the agency relies on post-market surveillance and facility inspections rather than pre-market approval.
How does a drug receive accelerated approval from the FDA?
The accelerated approval pathway, established in 1992, allows drugs treating serious conditions with unmet medical need to reach the market based on surrogate endpoints — laboratory measurements or physical signs that reasonably predict clinical benefit. Sponsors must complete post-market confirmatory trials to verify actual patient benefit; failure to do so has led to recent product withdrawals, including multiple oncology indications withdrawn between 2021 and 2023.
What is the practical difference between CDER and CBER at the FDA?
CDER, the Center for Drug Evaluation and Research, oversees small-molecule drugs and therapeutic proteins. CBER, the Center for Biologics Evaluation and Research, regulates vaccines, blood products, gene therapies, and cellular therapies. This structural split means that a gene-edited cell therapy and a traditional small-molecule drug travel through different review divisions with distinct regulatory precedents and reviewer expertise.
How does the user fee system affect FDA review timelines?
Since PDUFA was first enacted in 1992, pharmaceutical and medical device companies have paid fees with their marketing applications. In exchange, the FDA commits to specific review deadlines — typically 6 to 12 months for standard applications and 4 to 8 months for priority review. The user fee reauthorization, which must pass Congress every five years, is a significant legislative event that can reshape agency priorities and performance targets.
Which industries does the FDA explicitly not regulate?
The FDA does not regulate the practice of medicine itself — that falls to state medical boards. It does not oversee dietary supplements with the same pre-market rigor applied to drugs; supplements enter the market without FDA approval, though the agency can act against adulterated or misbranded products after they reach consumers. Insurance coverage, drug pricing, and clinical trial design ethics are also outside its statutory authority.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: